Abstract: Slide Presentations |


Aditya Gupta, MD*; Marcus Kennedy, MD; Roberto Casal, MD; Carlos A. Jimenez, MD; Rodolfo C. Morice, MD; David E. Ost, MD; Mona Sarkiss, MD; David Rice, MD; George A. Eapen, MD
Author and Funding Information

University of Texas Health Science Center - Houston, Houston, TX


Chest. 2009;136(4_MeetingAbstracts):1S. doi:10.1378/chest.136.4_MeetingAbstracts.1S-h
Text Size: A A A
Published online


PURPOSE:  Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is an accurate modality for evaluation of mediastinal and hilar masses and lymphadenopathy. We sought to identify the various factors affecting the diagnostic yield of EBUS-TBNA.

METHODS:  A review was performed of the first 235 patients who underwent 236 real-time EBUS-TBNA at our institution in 2005; nine procedures included in the analysis were for hilar /mediastinal masses and not lymphadenopathy. Cytological analysis of EBUS-TBNA aspirates were compared to a reference standard of definitive pathological tissue diagnosis or a composite of ≥6 month's clinical follow-up with radiographic imaging by two reviewers.

RESULTS:  Sampling accuracy was found to be slightly lower in the paratracheal lymph nodes (84.1%), compared with either the hilar (91.2%) or the subcarinal lymph nodes (93.2%) (p=0.009). The mean lymph node size sampled was 11.41 +/− 0.23 mm. Sampling with EBUS-TBNA was less accurate in lymph nodes ≤5mm (64.7%) compared to lymph nodes >5 mm in diameter (92%) (p=0.0001). Prior cancer therapy was not associated with a statistically significant reduction in the diagnostic yield of EBUS-TBNA in comparison to primary staging in patients with NSCLC. EBUS-TBNA had an overall sensitivity of 86.1% (95% CI: 0.796–0.926), specificity of 100% (95% CI: 0.966–1.00) and the diagnostic yield ranged from 83%–100% for malignancies of varying pathology (p=0.62).

CONCLUSION:  Factors that appear to influence the diagnostic yield of EBUS-TBNA include lymph node size and location (lymph nodes ≤5 mm and those in paratracheal location have a lower diagnostic yield). Histological type of the malignancy and a history of prior treatment (chemotherapy, radiation therapy or both) did not appear to affect the diagnostic yield of EBUS-TBNA.

CLINICAL IMPLICATIONS:  EBUS-TBNA can be used as an initial diagnostic tool for the evaluation of mediastinal and hilar masses that are greater than 5 mm in size, irrespective of their histological type. Diagnostic yield is lower for sampling lymph nodes in the paratracheal than in the hilar or subcarinal location.

DISCLOSURE:  Aditya Gupta, No Financial Disclosure Information; No Product/Research Disclosure Information

Monday, November 2, 2009

10:30 AM - 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543